Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388457 | 0.86 | GPR119 (0.62) | GPR119 | |
| SCHEMBL5190100 | 0.81 | GPR119 (0.55) | GPR119 | |
| SCHEMBL389360 | 0.81 | GPR119 (0.68) | GPR119 | |
| SCHEMBL389325 | 0.81 | GPR119 (0.60) | GPR119CA1CA2CA7CA13 | |
| SCHEMBL3163892 | 0.80 | GPR119 (0.61) | GPR119 | |
| SCHEMBL27652036 | 0.79 | GPR119 (0.46) | GPR119CA1CA2CA7CA13 | |
| SCHEMBL389917 | 0.78 | GPR119 (0.64) | GPR119 | |
| SCHEMBL2784216 | 0.77 | GPR119 (0.59) | GPR119 | |
| SCHEMBL3164609 | 0.77 | GPR119 (0.58) | GPR119 | |
| SCHEMBL390181 | 0.76 | GPR119 (0.59) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |